BACKGROUND: RC-3095, a synthetic gastrin-releasing peptide (GRP) antagonist, has been identified as a candidate compound for the treatment of tumor necrosis factor (TNF)-dependent chronic inflammatory conditions. AIM: The aim of this study was to evaluate the effects of RC-3095 in a rat model of ulcerative colitis. METHODS: Ninety Wistar rats were included in the study. Colitis was induced by a single intracolonic application of acetic acid. Rats were divided into three groups of treatment: subcutaneous RC-3095, intracolonic mesalazine, and subcutaneous dexamethasone. Additionally, there was a fourth group of animals submitted to induction of colitis without receiving any form of treatment, and a fifth group in which no colitis was induced. Seventy-two hours after instillation of acetic acid, the animals were killed and the following parameters were assessed: morphological score of damage, histological score of colonic inflammation, and immunohistochemical expression of TNF-alpha and interleukin (IL)-1beta. RESULTS: RC-3095 was the only treatment to significantly reduce macroscopic and microscopic scores of inflammation as compared with the animals from the non-treated colitis group. RC-3095 also significantly reduced the colonic expression of TNF-alpha, but not the expression of IL-1beta. CONCLUSIONS: RC-3095 reduced the colitis severity in a well-established experimental model of IBD. The anti-inflammatory activity of this compound was associated with a reduction in the colonic expression of TNF-alpha. These results suggest that interference with GRP pathway might represent a potential new strategy for the treatment of ulcerative colitis that deserves further investigational studies.
BACKGROUND: RC-3095, a synthetic gastrin-releasing peptide (GRP) antagonist, has been identified as a candidate compound for the treatment of tumor necrosis factor (TNF)-dependent chronic inflammatory conditions. AIM: The aim of this study was to evaluate the effects of RC-3095 in a rat model of ulcerative colitis. METHODS: Ninety Wistar rats were included in the study. Colitis was induced by a single intracolonic application of acetic acid. Rats were divided into three groups of treatment: subcutaneous RC-3095, intracolonic mesalazine, and subcutaneous dexamethasone. Additionally, there was a fourth group of animals submitted to induction of colitis without receiving any form of treatment, and a fifth group in which no colitis was induced. Seventy-two hours after instillation of acetic acid, the animals were killed and the following parameters were assessed: morphological score of damage, histological score of colonic inflammation, and immunohistochemical expression of TNF-alpha and interleukin (IL)-1beta. RESULTS: RC-3095 was the only treatment to significantly reduce macroscopic and microscopic scores of inflammation as compared with the animals from the non-treated colitis group. RC-3095 also significantly reduced the colonic expression of TNF-alpha, but not the expression of IL-1beta. CONCLUSIONS: RC-3095 reduced the colitis severity in a well-established experimental model of IBD. The anti-inflammatory activity of this compound was associated with a reduction in the colonic expression of TNF-alpha. These results suggest that interference with GRP pathway might represent a potential new strategy for the treatment of ulcerative colitis that deserves further investigational studies.
Authors: A D Millar; D S Rampton; C L Chander; A W Claxson; S Blades; A Coumbe; J Panetta; C J Morris; D R Blake Journal: Gut Date: 1996-09 Impact factor: 23.059
Authors: E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald Journal: Gastroenterology Date: 1994-06 Impact factor: 22.682
Authors: P G Oliveira; C V Brenol; M I Edelweiss; J C T Brenol; F Petronilho; R Roesler; F Dal-Pizzol; G Schwartsmann; R M Xavier Journal: Peptides Date: 2008-06-12 Impact factor: 3.750
Authors: Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen Journal: Peptides Date: 2015-05-11 Impact factor: 3.750
Authors: Vera L Oliveira-Freitas; Leonardo Dalla Giacomassa Rocha Thomaz; Lucas Elias Lise Simoneti; Christiane Malfitano; Kátia De Angelis; Jane Maria Ulbrich; Gilberto Schwartsmann; Cristiano Feijó Andrade Journal: Biomed Res Int Date: 2015-03-29 Impact factor: 3.411